The stock of LAVA Therapeutics NV (LVTX) has seen a -5.83% decrease in the past week, with a -49.22% drop in the past month, and a -39.38% decrease in the past quarter. The volatility ratio for the week is 8.57%, and the volatility levels for the past 30 days are at 10.79% for LVTX. The simple moving average for the last 20 days is -6.44% for LVTX stock, with a simple moving average of -51.68% for the last 200 days.
Is It Worth Investing in LAVA Therapeutics NV (NASDAQ: LVTX) Right Now?
The 36-month beta value for LVTX is at 0.55. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for LVTX is 14.17M, and currently, shorts hold a 0.41% of that float. The average trading volume for LVTX on January 10, 2025 was 107.24K shares.
LVTX) stock’s latest price update
LAVA Therapeutics NV (NASDAQ: LVTX)’s stock price has decreased by -4.91 compared to its previous closing price of 1.02. However, the company has seen a -5.83% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-10 that UTRECHT, The Netherlands and PHILADELPHIA, Jan. 10, 2025 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, announced dosing of the first patient in the Phase 1, first-in-human study of the CD123-targeted Gammabody®, LAVA-1266, an investigational agent in development for the treatment of hematologic cancers including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Analysts’ Opinion of LVTX
Many brokerage firms have already submitted their reports for LVTX stocks, with Leerink Partners repeating the rating for LVTX by listing it as a “Market Perform.” The predicted price for LVTX in the upcoming period, according to Leerink Partners is $2 based on the research report published on December 12, 2024 of the previous year 2024.
H.C. Wainwright gave a rating of “Buy” to LVTX, setting the target price at $9 in the report published on October 25th of the previous year.
LVTX Trading at -32.72% from the 50-Day Moving Average
After a stumble in the market that brought LVTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.01% of loss for the given period.
Volatility was left at 10.79%, however, over the last 30 days, the volatility rate increased by 8.57%, as shares sank -34.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -52.83% lower at present.
During the last 5 trading sessions, LVTX fell by -6.80%, which changed the moving average for the period of 200-days by -74.12% in comparison to the 20-day moving average, which settled at $1.0362. In addition, LAVA Therapeutics NV saw 1.99% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for LVTX
Current profitability levels for the company are sitting at:
- -3.82 for the present operating margin
- 0.95 for the gross margin
The net margin for LAVA Therapeutics NV stands at -3.76. The total capital return value is set at -0.41. Equity return is now at value -63.12, with -28.44 for asset returns.
Based on LAVA Therapeutics NV (LVTX), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -4.91.
Currently, EBITDA for the company is -40.42 million with net debt to EBITDA at 0.76. When we switch over and look at the enterprise to sales, we see a ratio of 0.66. The receivables turnover for the company is 7.17for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.36.
Conclusion
In conclusion, LAVA Therapeutics NV (LVTX) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
